The effects of peritoneal dialysis on the single dose and steady state pharmacokinetics of valproic acid in a uremic epileptic child.
The pharmacokinetics of valproic acid (VPA) have been studied during peritoneal dialysis in a uremic male epileptic child following a single 500 mg dose and after multiple doses over 5 months (700 mg daily) of valproic acid as the syrup. Serum level decline was biphasic in both instances with a terminal half-life of 27.2 after the single dose and 10.2 h at steady-state. Total serum clearance was 0.0236 l/h/kg after the single dose and increased to 0.0408 l/h/kg after 5 months. Free (intrinsic) serum clearances were 0.1489 and 0.1518 l/h/kg and serum free fractions were 0.224 and 0.272 respectively for the single dose and steady-state studies. Peritoneal dialysis for periods of 12 or 24 h removed an average of 4.5% of the VPA dose.
D002648:Child; D004827:Epilepsy / Q000150:complications* / Q000188:drug therapy; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D010530:Peritoneal Dialysis; D014511:Uremia / Q000150:complications / Q000378:metabolism*; D014635:Valproic Acid / Q000008:administration & dosage / Q000378:metabolism*
D014635:Valproic Acid